Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-26-191565
Filing Date
2026-04-29
Accepted
2026-04-29 16:11:35
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A for_filing_2026_defa14a.htm DEFA14A 24760
2 GRAPHIC img54669493_0.jpg GRAPHIC 274885
3 GRAPHIC img54669493_1.jpg GRAPHIC 148175
  Complete submission text file 0001193125-26-191565.txt   608768
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39527 | Film No.: 26916129
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)